Form 4: Stoke Therapeutics CMO Sells Shares Post-RSU Vesting
Insider Transaction Report
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported the vesting of restricted stock units and subsequent sales of common stock to cover tax obligations.
Summary
- Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported transactions related to his beneficial ownership.
- On December 1, 2025, 11,981 restricted stock units (RSUs) vested, resulting in the acquisition of 11,981 shares of common stock at a price of $0.
- Following this acquisition, Mr. Ticho beneficially owned 19,176 shares of common stock.
- Between December 2, 2025, and December 3, 2025, a total of 4,020 shares of common stock were disposed of in multiple transactions.
- These sales were mandated by the Issuer to satisfy tax withholding liabilities associated with the vesting and settlement of the restricted stock units.
- The sales occurred at weighted average prices ranging from $29.562 to $30.8477 per share.
- After all reported transactions, Mr. Ticho beneficially owned 15,156 shares of common stock.
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions related to RSU vesting and tax withholding, which are neither inherently positive nor negative for the company's operational or financial performance.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape.
Stakeholder Impact
- Minimal direct impact on shareholders as these are routine compensation-related transactions by an insider and do not indicate a change in company fundamentals or management's long-term view.
Key Dates
| Date | Description |
|---|---|
| 12/01/2024 | 48,792 restricted stock units vested. |
| 12/01/2025 | 11,981 restricted stock units vested and 11,981 shares of common stock were acquired. |
| 12/02/2025 | Sale of 1,244 common shares at a weighted average price of $29.562 and 762 common shares at a weighted average price of $30.1419 to satisfy tax withholding liabilities. |
| 12/03/2025 | Sale of 789 common shares at a weighted average price of $30.338 and 1,225 common shares at a weighted average price of $30.8477 to satisfy tax withholding liabilities. |
Recommendation
holdThe Form 4 details routine insider transactions involving the vesting of restricted stock units and subsequent sales to cover tax obligations. These transactions are a standard part of executive compensation and do not reflect a change in the company's fundamentals or the insider's long-term view of the company. Therefore, it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Stoke Therapeutics, STOK, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Barry Ticho, Chief Medical Officer, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.